Tadekinig alfa
Phase 1Small molecule
Tadekinig alfa is one of 4 small molecule programs targeting Cytokine Release Syndrome. It is currently in Phase 1.
1
Indications
4
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Cytokine Release Syndrome
#DrugCompanyPhaseTrials
1Tecvayli
Johnson & JohnsonPhase 2
Remicade
Johnson & JohnsonPhase 2
TALVEY
Johnson & JohnsonPhase 2
Tadekinig alfa
AAB2 Bio Ltd.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cytokine Release Syndrome1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tadekinig alfa. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- AAB2 Bio Ltd.